Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1[Inebilizumab]
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 300 💬
2INEBILIZUMAB
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[8] 11, 13, 46, 49, 51, 53, 95, 300 💬
3Inebilizumab + Rapid Steroid Tapering group
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
4Inebilizumab + Standard Steroid Tapering group
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
5Rapid-tapering glucocorticoids + Inebilizumab
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬
6Slow-tapering glucocorticoids + Inebilizumab
(D11757)
[1] Inebilizumab[1] Inebilizumab (D11757) 💬 [1] CD19 💬 [5] B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬[1] 13 💬